K. Siezen, PhD

Dutch Medicines Evaluation Board (MEB)

Speaker Module B

Christine Siezen (Kris) obtained her PhD from the University of Rotterdam, followed by a post-doctoral position at the National Institute of Public Health and Environment (RIVM), both in the field of molecular epidemiology and cancer research. Since 2007 she is a preclinical pharmaceutical assessor at the Medicines Evaluation Board (CBG-MEB) in Utrecht. Her role involves the assessment of the pharmacological, pharmacokinetic and toxicological parts of the dossier of new pharmaceuticals. Leading on from this is a special interest in the development of alternative and more relevant testing strategies to facilitate correct evaluation of pharmaceuticals. To be involved in the development and implementation of these alternatives, she is an active contributor to several research projects on collaboration with RIVM and Leiden Academic Centre for Drug Research (LACDR). Besides her role as an assessor, Kris is a project leader focusing on innovations in pharmaceutical development and drug regulation.